- Research article
- Open Access
OSMR gene effect on the pathogenesis of chronic autoimmune Urticaria via the JAK/STAT3 pathway
© The Author(s) 2018
- Received: 19 January 2018
- Accepted: 6 May 2018
- Published: 5 June 2018
Chronic autoimmune urticaria (CAU) is a common skin disease and remains unclear understanding of pathogenesis in the vast majority of cases. In order to explore a new therapy for CAU, the current study was performed to investigate the possible functioning of the Oncostatin M receptor (OSMR) gene in the autoimmunity of CAU via regulation of the JAK/STAT3 signaling pathway.
CAU skin tissues from 24 CAU patients and normal skin tissues from normal subjects were collected. Hematoxylin-eosin (HE) staining was conducted to count eosinophils, and immunohistochemistry was carried out to detect the positive rate of OSMR expression in two kinds of skin tissues. A total of 72 Kunming (KM) mice were selected, and 60 mice were used for establishing CAU models and later transfected with different plasmids. The expression of inflammatory factors was evaluated by enzyme-linked immunosorbent assays (ELISA). Expressions of janus kinase (JAK), signal transducer and activator of transcription 3 (STAT3), interferon-stimulated gene 15 (ISG15), CT10-regulated kinase (CRK), and interferon regulatory factor 9 (IRF9) were identified using Western blot assay and reverse transcription quantitative polymerase chain reaction (RT-qPCR). Epithelial cell proliferation was assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay, and cell cycle distribution and cell apoptosis were assessed using flow cytometry.
The findings confirm that OSMR protein expression and histamine release rate are highly elevated in human CAU skin tissues, and the expression of the JAK/STAT3 signaling pathway-related genes (OSMR, JAK2, STAT3, ISG15, CRK and IRF9) was up-regulated. OSMR gene silencing in CAU mice significantly decreases the content of inflammatory factors (IL-1, IL-6, IFN-γ, and IgE), the number of eosinophils, and reduces the expression of the JAK/STAT3 signaling pathway related genes, and further enhances cell proliferation, promotes cell cycle entry and inhibits apoptosis of epithelial cells.
All aforementioned results indicate that OSMR gene silencing inhibits the activation of the JAK/STAT3 signaling pathway, thereby suppressing the development of CAU.
- OSMR gene
- JAK/STAT3 signaling pathway
- Chronic autoimmune urticaria
Chronic urticaria (CU), an immune-mediated inflammatory disease, is defined as the spontaneous or inducible appearance of hives, angioedema or both lasting at least 6 weeks and presenting with numerous subtypes, all greatly damage patients’ quality of life (Bingham 3rd, 2008; Gimenez-Arnau et al., 2015). CU, the potentially debilitating skin condition, is known to affect up to 1% of the general population with different durations, usually several months, but occasionally decades (Ventura et al., 2013). Chronic idiopathic urticaria (CIU) is a common type of CU accounting for over 70% cases of CU, and chronic autoimmune urticaria (CAU), a subgroup of CIU, accounts for more than 30% of CIU. CIU is characterized by severe and persistent wheals accompanied by redness and itching (Goh & Tan, 2009; Abd El-Azim & Abd, 2011). CAU is caused by anti-FcepsilonRI and less normally, by anti-IgE autoantibodies that result in the activation of mast cells and basophils (Goh & Tan, 2009). Currently, clinical suspicion and autologous serum skin test (ASST) are regarded as the basis of CAU diagnosis (Abd El-Azim & Abd, 2011). Previously, the role of omalizumab in treating refractory CAU patients was studied, and proven possible (Al-Ahmad, 2010). In addition, mizoribine was found to be an effective therapy in some CAU patients, and may possibly be effective for patients not responsive to traditional therapy (Hashimoto et al., 2012). CAU patients are poor responders to antihistamine therapy, which leads to the necessity of immunosuppressive therapy (Cherrez Ojeda et al., 2009). Therefore, new genetic methods are required to find the possible ways for the treatment of CAU.
Oncostatin M (OSM), a member of the interleukin 6 (IL-6) family of cytokines, plays important roles in various biological functions, including inflammatory responses and metabolic diseases (Komori et al., 2013). OSM secreted by skin-infiltrating T-lymphocytes is considered to be a potential keratinocyte activator correlated to skin inflammation (Boniface et al., 2007). Oncostatin M receptor (OSMR) gene is located at 5p13.1, and can bind to gp130 to mediate the biological functions of OSM (Hong et al., 2011; Deng et al., 2009). Therapies based on OSMR have been reported for treatment of various cancers including cervical squamous cell carcinoma and lung adenocarcinomas, as well as skin diseases such as familial primary localized cutaneous amyloidosis (Caffarel & Coleman, 2014; Chen et al., 2008; Arita et al., 2008). Janus kinase-signal transducer and activator of transcription (JAK/STAT) transmits information received from extracellular polypeptide signals through transmembrane receptors, directly to the target gene promoters in the nucleus, providing a mechanism for regulation of transcriptional without second messengers (Aaronson & Horvath, 2002). JAKs are required for numerous inflammatory cytokine signaling pathways, and are implicated in the pathogenesis of chronic dermatitis, atopic dermatitis and psoriasis, and JAK inhibitors are thus promising therapeutic candidates for chronic dermatitis (Tanimoto et al., 2018). Additionally, JAK inhibitors, which are also used to inhibit cytokine signaling, are assumed to be a possible mean of treating skin inflammatory disorders such as contact dermatitis (Amano et al., 2016). It has been reported that OSM is released in inflammatory conditions, and it signals primarily via the JAK/STAT pathway by combining with its receptor complex (Hermanns, 2015). The heterodimeric receptor complex combined with gp130 and OSMR could activate a signaling pathway involved in JAKs as well as transcription factors of the STAT family (Hintzen et al., 2008). However, further verification is required in order to explore whether the OSMR gene is involved in the pathogenesis of CAU through the JAK/STAT3 signaling pathway. Therefore, the current study aims to explore the role of OSMR gene silencing in the pathogenesis of CAU and its underlying mechanism involving the JAK/STAT3 signaling pathway.
This study was approved by the Ethics Committee of Children’s Hospital of Chongqing Medical University, and signed informed consents were obtained from all patients/guardians. In addition, the experiments were in accordance with the ethical standards, and all efforts were made to minimize the suffering of the animals included in the study.
CAU skin tissues from 24 CAU patients of Children’s Hospital of Chongqing Medical University were collected, and normal skin tissues from skin grafts of 24 plastic surgery patients were selected as controls. Skin biopsy specimens were rapidly frozen in liquid nitrogen in order to prevent protein denaturation until total RNA was extracted from the specimens. The 24 CAU patients included 11 males and 13 females, with a mean age of 10 years. The average courses of disease of patients were 6.67 months (range 2–16 months). All patients had been treated with antihistaminic agents, and some patients underwent treatment with corticosteroids but with poor efficacy, for 16 of them complained of joint pain, gastrointestinal or respiratory symptoms.
Hematoxylin-eosin (HE) staining
Skin tissues extracted from CAU patients were fixed in 4% paraformaldehyde for 24 h, washed, dehydrated, cleared, waxed, embedded, sectioned, and made into paraffin sections. After that, the sections were stained with hematoxylin for observing the eosinophil infiltration in skin tissue of patients.
The sections underwent routine dewaxing, dehydration with gradient ethanol, antigen-repair under high pressure for 1.5 min, and cooling under tap water for 10 min. After the remaining tap water on the sections was removed under running water, the sections were added one drop of endogenous peroxidase blocking solution, incubated at room temperature for 10 min, and rinsed with phosphate buffer solution (PBS) (3 min, 3 times). Then, the sections were added with suitable amount of primary antibody, namely rabbit anti human immunoglobulin G (IgG) antibody for incubation overnight at 4 °C, followed by rinsing with PBS after being taken out (3 min, 3 times), and incubation with the biotin-labeled secondary mouse anti rabbit monoclonal antibody IgG/horseradish peroxidase (HRP) (dilution ratio of 1: 1000, ab6759, Abcam, Inc., Cambridge, MA, USA) at 37 °C for 30 min. After incubation with the two types of antibodies, the sections were rinsed with PBS (3 min, 3 times), dealt by streptomyces anti biotin catalase complex for 15 min, colored with 3,3′-diaminobenzidine (DAB), and then rinsed under tap water to terminate the whole reaction. Later, the sections were re-stained with hematoxylin, dehydrated, cleared, and mounted. PBS was used as the negative control instead of the primary antibody. Finally, each section was randomly photographed under a light microscope (at 10× & 40× magnification) to get 5 non-overlapping visual fields. At last, 100 cells were counted in each visual field randomly, and the percentage of positive cells = positive cells/total cells.
CAU animal model establishment
A total of 72 Kunming (KM) mice weighing 18~ 25 g (J018, Better Biotechnology Co., Ltd., Nanjing, China) were selected for the study, amongst which 60 mice were used for the establishment of CAU mouse models, and the other 12 untreated mice were regarded as the normal group. Each intraplantar of mice was treated with 0.05 mL 5% physiological saline solution containing ovalbumin (the total amount of injection for a mouse was 0.1 mL). Meanwhile, each mouse received pertussis vaccines (4 × 109 U) via intraperitoneal injections. After 12–14 d, the mice were sacrificed by using the neck-breaking method and blood was drawn. Mice blood was collected and centrifuged in order to separate the antiserum, which was stored in a refrigerator for later use (mixed antisera was selected from 5 sensitized mice). With the addition of normal saline (dilution ratio of 1: 10), 0.03 m1L antiserum was injected into the abdominal wall of the mice. Subsequently, antigen attack was conducted by injections of 1 mL normal saline (containing 1 mg ovalbumin). The indications of pruritus include systemic pruritus-head scratching by paw, torso scratching by hind claws, and biting all parts of the body by mouth. The number and total duration of pruritus in each mouse was recorded within 30 min of the 1 mL dextran injections through the tail vein. The CAU mouse model was considered to be successfully established if the number and total duration of pruritus were significantly higher than the normal mice (Yagami et al., 2017). A total of 60 mice were successfully established as CAU models which were classified into: the blank group (model mice without any treatment), the negative control group (NC) (model mice transfected with empty vector plasmid), the OSMR-siRNA group (model mice transfected with OSMR-siRNA plasmid), the anti-phospho-STAT3 (Tyr705) + OSMR-siRNA group (model mice transfected with OSMR-siRNA plasmid + the JAK/STAT3 signaling pathway agonist), and the Tyr705 group (model mice treated with the JAK/STAT3 signaling pathway agonist) groups. The plasmids used in the experiments were purchased from Vigene Biotechnology Co., Ltd. (Shandong, China). Then, attention was paid to the number and total duration of pruritus within 30 min. The mice were sacrificed after successful transfection with corresponding plasmids. Then, mice skin specimens with wheal or rash were extracted and stored at − 80 °C. Eosinophil counting was conducted by routine method and the absolute value was recorded.
Isolation and culture of mast cells
The foreskin of children (1–9 years) was extracted by circumcision under aseptic conditions. The skin grafts were incubated in a RPMI 1640 culture medium (containing 100 U/mL penicillin and 100 μg/mL streptomycin) after blood was removed using normal saline. Subcutaneous tissues were isolated and rinsed with modified Tyrode solution (containing 137 mmol/L NaCl, 2.7 mmol/L KCl, 0.4 mmol/L NaH2PO4, 5.6 mmol/L Glucose, 10 mmol/L HEPES, 1 mmol/L CaCl and 1 mmol/L MgCl2). Subsequently, the skin grafts were cut sliced tissue fragments of 1 mm2, and placed in RPMI 1640 culture medium containing 1.5 mg/mL type I collagenase and 0.5 mg/mL hyaluronidase for 4-h culturing in an incubator containing 5% CO2 in air and saturated humidity at 37 °C. Next, the fragments were isolated in order to a form a cell suspension by repeated blowing and beating of digestive juice with a straw. The suspension was filtrated with a stainless steel filter net. After removal of the tissue fragments and larger cell clusters, the filtrate was collected, rinsed with icy Tyrode solution, re-suspended in a RPMI 1640 culture medium containing 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin, and cultured in a 5% CO2 incubator with saturated humidity at 37 °C for 12 h. Subsequently, the culture medium was collected after gently shaking the culture bottle.
Histamine release test and enzyme linked immunosorbent assay (ELISA)
A total of 75 μL serum samples and normal serum samples obtained from CAU patients and healthy individuals were respectively mixed with 75 μL mast cell suspension, and incubated at 37 °C for 20 min, followed by centrifugation at 1610×g for 15 min, and the supernatant was collected which was used for evaluation of histamine release rate (the compound tube was used for aforementioned evaluation). The histamine release rate in CAU patients and normal individuals was determined by ELISA. Firstly, the test sample and reagent kit (ZK-G7274, Zike Biotechnology Co., Ltd., Shenzhen, China) were subjected to acylation and dilution following the standard and quality control in accordance with the operating procedures. Then, 50 μL test serum samples were obtained from CAU patients and healthy individuals. A total of 50 μL polyclonal anti-histamine antibody, enzyme conjugates and histamine antiserum were added into each well successively, which were mixed evenly and incubated at room temperature for 3 h, followed by plate rinsing five times. After that, the freshly prepared 200 μL 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution was added into each well for further incubation at room temperature for 20 min, followed by plate rinsing five times, and pat to dry the plate. Later, 100 μL TMB stop solution was added to each well to terminate the reaction, and the absorbance (A) value measured using a microplate reader at the excitation wavelength of 450 nm. Content of histamine in samples was calculated using a standard curve, and the formula was as follows: X = A × 50/m. The histamine spontaneous release rate = histamine spontaneous release/total histamine content × 100%, and histamine release rate of samples = histamine content/total histamine content × 100%. Interleukin-1 (IL-1) ELISA kit (SBJ-M0582), IL-6 ELISA kit (SBJ-M0044), interferon (IFN)-γ ELISA kit (SBJ-M0038), IgE ELISA kit (SBJ-M0499) were used to measure the contents of IL-1, IL-6, IFN-γ and IgE according to the protocols provided by the manufacturer. All the kits were purchased from Nanjing SenBeiJia Biological Technology Co., Ltd. (Nanjing, Jiangsu, China).
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
RT-qPCR primer sequences
R: 5’-GGCGATACTGCGACCCT − 3′
Western blot analysis
Skin tissues (100 mg) of each group were extracted, placed in a glass grinder containing 1 mL tissue lysate (BB-3209, Bestbio Technology, Co., Ltd., Shanghai, China), and were ground to a homogenate by ice-bath, where after protein lysate was added in for tissue splitting at 4 °C for 30 min, centrifuged at 1610×g, 4 °C for 15 min, and the supernatant was collected. A bicinchoninic acid (BCA) kit (2020ES76, Yeasen Company, Shanghai, China) was employed in order to detect the concentration of each tissue samples. Firstly, deionized water was added to adjust the sample quantity of 30 μg protein lane. Then, 10% sodium dodecyl sulfate (SDS) separating glue and concentration glue was prepared. The sample tissues were mixed with the sample buffer, heated to a boil for 5 min, ice-bathed, centrifuged before being added into each lane with a micropipette for lectrophoretic separation. After that, the proteins on the membrane were transferred onto a nitrocellulose membrane (ZY-160FP, Zeye Biology, Shanghai, China), blocked with 5% skimmed power at 4 °C overnight. Later, diluted primary antibody, namely rabbit anti human polyclonal antibodies (dilution ratio of 1: 500), including OSMR (11226-R007, dilution ratio of 1: 400, Sino Biological Inc., Beijing, China), JAK2 (ab32101, dilution ratio of 1: 1000, Abcam Inc., Cambridge, MA, USA), STAT3 (ab68153, dilution ratio of 1: 1000, Abcam Inc., Cambridge, MA, USA), ISG15 (LS-C211809, dilution ratio of 1: 1000, Littleton, Colorado, USA), IRF9 (PAB28499, dilution ratio of 1: 400, Lianshuo Biological Technology, Wuhan, Hubei, China) and p-STAT3 (sc-56,747, Univ-bio, Shanghai, China) were added into the membrane for overnight incubation, followed by rinsing with PBS (5 mins, 3 times). The secondary antibody mouse anti rabbit IgG/HRP (Huabio Inc., Hangzhou, Zhejiang, China) was added for rocking incubation at 37 °C for 1 h, followed by rinsing with PBS at room temperature (5 mins, 3 times). At room temperature, the membrane was reacted with enhanced chemiluminescence (ECL) solution for 1 min, after which the membrane was amounted using cling-film with the liquid removed, and observed under an X-ray instrument (36209ES01, Qianchen Bioteachnology, Shanghai, China). GAPDH was regarded as the internal reference, and the grey value ratio of target band and GAPDH band was taken as the relative expression of sample protein. Each experiment was conducted three times.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide (MTT) assay
Skin tissues were extracted from mice in order to obtain keratinocytes after detachment, isolation and culture. The cells were allowed to reach around 80% confluence, and were rinsed with PBS two times, and detached by trypsin in order to prepare a single cell suspension. After counting, the cells were seeded into a 96-well plate at a density of 3 × 103 ~ 6 × 103 cells/well, with the cell volume in each well maintained to 0.2 mL. A total of 6 duplicate wells were set, and the cells were cultured in an incubator. At the 30 min, 1 h, 6 h, 12 h, 24 h, and 48 h time periods during the incubation, the culture plate was taken out and the original culture medium was replaced with 5 g/L 10% MTT solution (GD-Y1317, Guduo Biotechnology Co., Ltd., Shanghai, China) for further 4-h incubation. Later, 100 μL dimethyl sulphoxide (DMSO) (D5879-100ML, Sigma-Aldrich Chemical Company, St Louis, MO, USA) were added in, and gently oscillated for uniform mixing for 10 min. After formazan crystals produced by living cells were dissolved with DMSO, the cell plate was placed onto a microplate reader for detecting the OD value of each well at the excitation wavelength of 490 nm. The experiment was repeated three times and the time point was set as the abscissa and the OD value as the ordinate in order to plot the CAU cell activity graph.
The mouse keratinocytes in the logarithmic phase of growth were selected, and isolated and cultured for 48 h. The cells were seeded in a 6-well plate at a density of 1 × 106 cells in each well and cultured in a 5% CO2 incubator at 37 °C until cell confluence reached 95%. Then, a vertical linear scratch was drawn using a 20 μl micropipette, and then serum-free medium was added to the wells after the 6-well plate was washed with D-hanks solution. Sample cells were collected after scratching at 0 h and 36 h time periods with 3 visual fields at 100X magnification were photographed under a phase contrast microscope in order to compare the different scratch lanes. The healing rate of the scratch line was regarded as the cell migration and healing ability.
The mouse keratinocytes were collected for detachment with 0.25% trypsin solution after isolation and culture for 48 h. The number of cell samples was adjusted to 1 × 106 mL− 1. Then, 1 mL cells were centrifuged at 402×g for 10 min with the supernatant discarded and the cells collected. Per mL of the collected cells were added with 2 mL PBS before undergoing centrifugation. The supernatant was discarded, and the cells were fixed with 70% pre-cooled ethanol solution at 4 °C overnight. The following day, the fixed cells were rinsed with PBS two times, and a cell suspension of 100 μL (containing more than 106 mL− 1) was selected, added with 1 mL 50 mg/L propidium iodide (PI) solution (containing RNAase) for 30-min incubation avoiding light exposure. After that, the cells were filtered with nylon net (300 mesh), and the cell cycle was analyzed using flow cytometry at an excitation wavelength of 488 nm.
Cell apoptosis was assessed using the Annexin V-fluorescein isothiocyanate (FITC)/PI double staining, and the cells were underwent the same process of cell cycle. The cells were cultured at 37 °C in an incubator containing 5% CO2 in air, and then were collected. After rinsing with PBS two times, the cells were centrifuged and re-suspended in 200 μL binding buffer, followed by the addition of fully-mixed 10 μL Annexin V-FITC and 5 μL PI for 15-min reaction avoiding light exposure at room temperature. Later, the cells were added with 300 μL binding buffer and placed onto the flow cytometry (6HT, Cellwar Bio-technology Co., Ltd., Wuhan, Hubei, China) for cell apoptosis detection at the excitation wavelength of 488 nm.
Statistical analyses were performed using the SPSS 22.0 software (IBM Corp. Armonk, NY, USA). Measurement data were expressed as mean ± standard deviation. Differences between two groups were compared using the t test, and differences among multiple groups were analyzed using one-way analysis of variance (ANOVA). p < 0.05 was considered to be statistically significant.
Elevated histamine releasing rate in CAU model mice signifies the successful model establishing
According to results of the histamine releasing by mast cells, the release rates of histamine by normal human serum activated mast cells were all negative, while 10 positive cases and 14 negative cases of histamine release out of human CAU serum were observed with the release rate of (21.35 ± 8.40)% which was higher than the normal subjects (9.08 ± 3.42)% (p < 0.05) (Fig. 1c). In CAU model mice, CAU mice with no transfection had a histamine release rate of (26 ± 5.20)% compared with normal mice which was (8.16 ± 4.28)%, signifying a highly increased histamine release rate in CAU model mice and successful establishment of CAU models (Fig. 1d).
Higher OSMR positive expression rate and elevated expression of the JAK/STAT3 signaling pathway-related genes in CAU skin tissues
As OSMR plays a vital role in CAU skin tissues, RT-qPCR and Western blot assay were conducted in order to elucidate the relationship between OSMR and the JAK/STAT3 signaling pathway. The results (Fig. 2c) reveal that the mRNA expression of OSMR and the JAK/STAT3 signaling pathway-related genes, including JAK2, STAT3, ISG15, CRK and IRF9, were evidently elevated in CAU skin tissues (p < 0.05), and the same was confirmed by the Western blot analysis (p < 0.05) (Fig. 2d). All aforementioned findings indicate that CAU exhibits increased expression of OSMR and the activated JAK/STAT3 signaling pathway.
Inhibited expression of CAU inflammatory factors as a result of OSMR silencing
Pathological reaction of CAU relieved and eosinophil number decreased after transfection with OSMR silencing
The number and duration of pruritus ratios in each group
Number of pruritus (time)
Duration of pruritus (min)
57.15 ± 6.72*
28.00 ± 4.10*
55.23 ± 4.38*
27.30 ± 3.90*
92.50 ± 7.80*#
40.50 ± 350*#
18.40 ± 5.10 *
17.00 ± 3.35*
Tyr705 + OSMR-siRNA
56.38 ± 5.20*#
29.40 ± 3.40*#
Enhanced proliferation of epithelial cells after transfected with OSMR silencing and the JAK/STAT3 signaling pathway inhibition
OSMR silencing inhibited the JAK/STAT3 signaling pathway thus suppressed CAU progression
Chronic autoimmune urticaria (CAU), a commonly occurring disease, is accompanied by various symptoms including transient eruption of itchy, edematous swellings of the dermis, and erythematosus, lasting over a duration of 6 weeks (Wardhana, 2012). Recent study has shown that OSMR plays an important role in systemic lupus erythematosus, and further leads to the stimulation of various cytokines and inflammatory substances, such as IL-6 and IL-11 by activating the JAK/STAT pathway and the mitogen-activated protein kinase (MAPK) signaling pathways (Lin et al., 2014). The current study has shown that OSMR gene silencing can restrain the development of CAU, which can be achieved through blocking the JAK/STAT3 signaling pathway.
Initially, it was found that OSMR silencing inhibits the expression of the JAK/STAT3 signaling pathway related-genes (JAK2, STAT3, ISG15, CRK and IRF9). JAK2 is a non-receptor tyrosine kinase responsible for diverse cellular processes via stimulating cytoplasmic signaling cascades (Dawson et al., 2009). STAT3, another gene of interest in the current study, is a key member of the JAK/STAT signaling pathway (Yau et al., 2012). ISG15 is an ubiquitin-like protein whose conjugation is involved in the antiviral immune response and regulation of the JAK/STAT signaling pathway (Osiak et al., 2005; Hsiao et al., 2010). CRK belongs to Src homology-2 (SH2) and SH3 domain comprised of proteins that controls the coordinated combination of signaling complexes (Sriram et al., 2015). IRF9 is a crucial factor in the JAK/STAT signaling pathway that stimulates the antiproliferative function of IFN-α (Wu et al., 2017; Tsuno et al., 2009). A previous study found that both type I and type II OSMR activated JAK1, JAK2, and TYK2 receptor-associated tyrosine kinases (Auguste et al., 1997). Recently, OSM has been reported to stimulate ISG genes participating in antigen processing as well as presentation (Hergovits et al., 2017). The OSMR protein has been reported to be capable of heterodimerizing with IL-6 signal transducer (gp130) in order to produce type II OSMR, and when the receptor complexes were taken in, JAK could be activated, followed by further activation of STAT3 (Hong et al., 2011). Consistently, it has been revealed that the low expression of OSMRβ could decrease atherogenesis by inactivating the JAK2/STAT3 signaling pathway in macrophages (Zhang et al., 2017). The aforementioned findings and evidence suggest that OSMR gene silencing could suppress the JAK/STAT3 signaling pathway.
Additionally, the current findings demonstrate that the contents of IL-1, IL-6, IFN-γ and IgE in serum of mice in the OSMR-siRNA group were significantly reduced, indicating that OSMR gene silencing suppressed the autoimmunity of CAU by blocking the JAK/STAT3 signaling pathway. Notable, it was reported that regulation of IFN-γ-secreting T helper 1 cells could inhibit autoimmunity and immunopathology (Cope et al., 2011). Previous studies have demonstrated that OSMR could increase IL-1 and TNF activity in synovial fibroblasts, which was consistent with the results of the current study (Le Goff et al., 2014). Interestingly, it was reported that inhibition of OSMR results in suppressed IL-31, which was highly expressed in the skin of patients with chronic spontaneous urticaria and was released from isolated basophils accompanied with anti-IgE activation (Raap et al., 2017). Moreover, it has been reported that inactivation of the JAK/STAT pathway could help in inhibiting the expression of ICAM-1 induced by IFN-γ in HaCaT human keratinocytes (Sung & Kim, 2013). The activated JAK/STAT signaling pathway could stimulate IFNs in order to exert an innate immune response (Cheng et al., 2014). In addition, STAT3 mutations are associated with autosomal dominant-hyper-IgE syndromes (AD-HIES) and this association might allow differentiation of AD-HIES from disorders correlated with elevated serum IgE levels (Schimke et al., 2010).
Consequently, it was revealed that OSMR gene silencing can obstruct the development of CAU by inhibiting the JAK/STAT3 signaling pathway, as increased proliferation, migration and decreased apoptosis of epithelial cells were observed in the OSMR-siRNA group. OSM, is a cytokine capable of modulating cell survival and proliferation, and the over-expression of OSM could result in transdifferentiation of epithelial-myofibroblast (Elbjeirami et al., 2010). In line with the findings of the current study, it was reported that over-expression of OSM in tubular epithelial cells might aggravate mucosal epithelial barrier dysfunction (Pothoven et al., 2015). The JAK/STAT is capable of modulating signaling cascades exerting great effects on proliferation, differentiation, development as well as immune responses (Kim et al., 2011). Additionally, it was reported that acute nitrogen dioxide exposure enhances airway inflammation that both humoral immunity and cellular immunity reaction via modulating Th1/Th2 differentiation and activating the JAK/STAT signaling pathway (Ji et al., 2015). Therefore, it can be hypothesized that OSMR gene silencing regulates proliferation, migration as well as apoptosis of epithelial cells in CAU by inhibiting the JAK/STAT signaling pathway.
The current study suggested that OSMR gene are highly expressed in human CAU skin tissues, and cause the up-regulation of the JAK/STAT3 signaling pathway-related genes. Additionally, it was demonstrated that OSMR gene silencing significantly decreases the content of inflammatory factors, the number of eosinophils, and reduces the mRNA and protein expressions of JAK/STAT3 signaling pathway-related genes, enhances cell proliferation, migration and inhibits apoptosis of epithelial cells. Thereby, it can be concluded that OSMR gene silencing inhibits autoimmunity in CAU mouse models by inactivating the JAK/STAT3 signaling pathway. These findings may open novel avenues for future CAU therapies and to ultimately, raise the quality of life of CAU patients. However, the limited sample size of the current study remains to be a limitation. Thus, further studies are warranted in order to better the understanding of specific mechanisms.
We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.
This work was supported by the National Natural Science Foundation of China (No. 81301362) and High End Talent Plan of Chongqing Municipal Health and Family Planning Commission.
HW and X-YL participated in the conception and design of the study. HW, QL and HY performed the analysis and interpretation of data. HY, QT and L-QG contributed to drafting the article. HW and F-LR revised it critically for important intellectual content. HW is the GUARANTOR for the article who accepts full responsibility for the work and/or the conduct of the study, had access to the data, and oversaw the decision to publish. All authors contributed to the revision and approved the final version of this manuscript.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Children’s Hospital of Chongqing Medical University and all patients or their guardians signed the informed consent. Besides, all animals disposed in the experiment were in accordance with the ethical standards.
Consent for publication
Consent for publication was obtained from the participants.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296:1653–5.View ArticlePubMedGoogle Scholar
- Abd El-Azim M, Abd E-AS. Chronic autoimmune urticaria: frequency and association with immunological markers. J Investig Allergol Clin Immunol. 2011;21:546–50.PubMedGoogle Scholar
- Al-Ahmad M. Omalizumab therapy in three patients with chronic autoimmune urticaria. Ann Saudi Med. 2010;30:478–81.PubMedPubMed CentralGoogle Scholar
- Amano W, et al. JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation. J Dermatol Sci. 2016;84:258–65.View ArticlePubMedGoogle Scholar
- Arita K, et al. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008;82:73–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Auguste P, et al. Signaling of type II oncostatin M receptor. J Biol Chem. 1997;272:15760–4.View ArticlePubMedGoogle Scholar
- Bingham CO 3rd. Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease. Curr Allergy Asthma Rep. 2008;8:278–87.View ArticlePubMedGoogle Scholar
- Boniface K, et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol. 2007;178:4615–22.View ArticlePubMedGoogle Scholar
- Caffarel MM, Coleman N. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol. 2014;232:386–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen D, et al. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas. J Pathol. 2008;215:290–9.View ArticlePubMedGoogle Scholar
- Cheng CH, et al. Differential regulation of Tetraodon nigroviridis mx gene promoter activity by constitutively-active forms of STAT1, STAT2, and IRF9. Fish Shellfish Immunol. 2014;38:230–43.View ArticlePubMedGoogle Scholar
- Cherrez Ojeda I, et al. Chronic autoimmune urticaria in children. Allergol Immunopathol (Madr). 2009;37:43–7.View ArticleGoogle Scholar
- Cope A, Le Friec G, Cardone J, Kemper C. The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching. Trends Immunol. 2011;32:278–86.View ArticlePubMedGoogle Scholar
- Dawson MA, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461:819–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Deng G, et al. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs. Clin Cancer Res. 2009;15:1519–26.View ArticlePubMedGoogle Scholar
- Denley SM, et al. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:887–98.View ArticlePubMedGoogle Scholar
- Elbjeirami WM, et al. Early differential expression of oncostatin M in obstructive nephropathy. J Interf Cytokine Res. 2010;30:513–23.View ArticleGoogle Scholar
- Gimenez-Arnau AM, Grattan C, Zuberbier T, Toubi E. An individualized diagnostic approach based on guidelines for chronic urticaria (CU). J Eur Acad Dermatol Venereol. 2015;29(Suppl 3):3–11.View ArticlePubMedGoogle Scholar
- Goh CL, Tan KT. Chronic autoimmune urticaria: where we stand? Indian J Dermatol. 2009;54:269–74.View ArticlePubMedPubMed CentralGoogle Scholar
- Hashimoto T, et al. Mizoribine treatment for antihistamine-resistant chronic autoimmune urticaria. Dermatol Ther. 2012;25:379–81.View ArticlePubMedGoogle Scholar
- Hergovits S, Mais C, Haan C, Costa-Pereira AP, Hermanns HM. Oncostatin M induces RIG-I and MDA5 expression and enhances the double-stranded RNA response in fibroblasts. J Cell Mol Med. 2017;21:3087–99.View ArticlePubMedPubMed CentralGoogle Scholar
- Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26:545–58.View ArticlePubMedGoogle Scholar
- Hintzen C, et al. Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation. J Biol Chem. 2008;283:19465–77.View ArticlePubMedGoogle Scholar
- Hong IK, Eun YG, Chung DH, Kwon KH, Kim DY. Association of the oncostatin m receptor gene polymorphisms with papillary thyroid cancer in the korean population. Clin Exp Otorhinolaryngol. 2011;4:193–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Hsiao NW, et al. ISG15 over-expression inhibits replication of the Japanese encephalitis virus in human medulloblastoma cells. Antivir Res. 2010;85:504–11.View ArticlePubMedGoogle Scholar
- Ji X, Han M, Yun Y, Li G, Sang N. Acute nitrogen dioxide (NO2) exposure enhances airway inflammation via modulating Th1/Th2 differentiation and activating JAK-STAT pathway. Chemosphere. 2015;120:722–8.View ArticlePubMedGoogle Scholar
- Kim BH, et al. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling. Exp Mol Med. 2011;43:313–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Komori T, Tanaka M, Senba E, Miyajima A, Morikawa Y. Lack of oncostatin M receptor beta leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. J Biol Chem. 2013;288:21861–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Le Goff B, et al. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. Cytokine. 2014;68:101–9.View ArticlePubMedGoogle Scholar
- Lin YZ, et al. Association of OSMR gene polymorphisms with rheumatoid arthritis and systemic lupus erythematosus patients. Autoimmunity. 2014;47:23–6.View ArticlePubMedGoogle Scholar
- Osiak A, Utermohlen O, Niendorf S, Horak I, Knobeloch KP. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol Cell Biol. 2005;25:6338–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Pothoven KL, et al. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015;136:737–46 e4.View ArticlePubMedPubMed CentralGoogle Scholar
- Raap U, et al. Human basophils are a source of - and are differentially activated by - IL-31. Clin Exp Allergy. 2017;47:499–508.View ArticlePubMedPubMed CentralGoogle Scholar
- Schimke LF, et al. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol 126. 2010;e1:611–7.View ArticleGoogle Scholar
- Sriram G, et al. Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk. Oncogene. 2015;34:4260–9.View ArticlePubMedGoogle Scholar
- Sung YY, Kim HK. Illicium verum extract suppresses IFN-gamma-induced ICAM-1 expression via blockade of JAK/STAT pathway in HaCaT human keratinocytes. J Ethnopharmacol. 2013;149:626–32.View ArticlePubMedGoogle Scholar
- Tanimoto A, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents. Exp Dermatol. 2018;27:22–9.View ArticlePubMedGoogle Scholar
- Tsuno T, et al. IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha. J Immunother. 2009;32:803–16.View ArticlePubMedPubMed CentralGoogle Scholar
- Ventura MT, Napolitano S, Menga R, Cecere R, Asero R. Anisakis simplex hypersensitivity is associated with chronic urticaria in endemic areas. Int Arch Allergy Immunol. 2013;160:297–300.View ArticlePubMedGoogle Scholar
- Wardhana DEA. Chronic autoimmune urticaria. Acta Med Indones. 2012;44:165–74.PubMedGoogle Scholar
- Wu Z, et al. Interaction of IRF9 and STAT2 synergistically up-regulates IFN and PKR transcription in Ctenopharyngodon idella. Mol Immunol. 2017;85:273–82.View ArticlePubMedGoogle Scholar
- Yagami A, Furue M, Togawa M, Saito A, Hide M. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2017;44:375–85.View ArticlePubMedGoogle Scholar
- Yau WW, Rujitanaroj PO, Lam L, Chew SY. Directing stem cell fate by controlled RNA interference. Biomaterials. 2012;33:2608–28.View ArticlePubMedGoogle Scholar
- Zhang X, et al. Oncostatin M receptor beta deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages. J Lipid Res. 2017;58:895–906.View ArticlePubMedPubMed CentralGoogle Scholar